Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Gardini, A. Casadei
613  Ergebnisse:
Personensuche X
?
1

287P Association of progression-free survival (PFS) with ov..:

Castet, F. ; Fabregat-Franco, C. ; Kim, J.W....
Annals of Oncology.  35 (2024)  - p. S121 , 2024
Link: https://doi.org/10.1016/..
 
?
2

300P Prognostic and predictive role of FGFR2 and IDH1 targe..:

Genovesi, V. ; Rimini, M. ; Pressiani, T....
Annals of Oncology.  35 (2024)  - p. S127 , 2024
Link: https://doi.org/10.1016/..
 
?
3

CXCL3 is a target of miR-30e-3p and predicts tumor escape i..:

Vianello, C. ; Leoni, I. ; Galvani, G....
Digestive and Liver Disease.  56 (2024)  - p. S94 , 2024
Link: https://doi.org/10.1016/..
 
?
4

293P Durvalumab plus gemcitabine and cisplatin in advanced ..:

Gardini, A. Casadei ; Fornaro, L. ; Lonardi, S....
Annals of Oncology.  35 (2024)  - p. S124 , 2024
Link: https://doi.org/10.1016/..
 
?
5

292P Extended molecular profiling (EMP) and access to targe..:

Genovesi, V. ; Rimini, M. ; Pressiani, T....
Annals of Oncology.  35 (2024)  - p. S123 , 2024
Link: https://doi.org/10.1016/..
 
?
6

184P Lenvatinib (L) versus sorafenib (S) second-line therap..:

Persano, M. ; Rimini, M. ; Foti, S....
Annals of Oncology.  35 (2024)  - p. S83 , 2024
Link: https://doi.org/10.1016/..
 
?
7

185P The combined role of patients (pts) gender and disease..:

Cesario, S. ; Genovesi, V. ; Rimini, M....
Annals of Oncology.  35 (2024)  - p. S83 , 2024
Link: https://doi.org/10.1016/..
 
?
8

MiR-22 regulates HIF-1A pathway and tumor progression and r..:

Galvani, G. ; Leoni, I. ; Monti, E....
Digestive and Liver Disease.  56 (2024)  - p. S96-S97 , 2024
Link: https://doi.org/10.1016/..
 
?
9

182P A real-world, multicenter study of atezolizumab plus b..:

Rossari, F. ; Tada, T. ; Shimose, S....
Annals of Oncology.  35 (2024)  - p. S82 , 2024
Link: https://doi.org/10.1016/..
 
?
10

Prognostic impact of previous intraarterial treatment in pa..:

Stefanini, B. ; Ielasi, L. ; Pressiani, T....
Digestive and Liver Disease.  55 (2023)  - p. S54-S55 , 2023
Link: https://doi.org/10.1016/..
 
?
11

93P The survival impact of the addition of durvalumab to ci..:

Rimini, M. ; Persano, M. ; Fornaro, L....
Immuno-Oncology and Technology.  20 (2023)  - p. 100565 , 2023
Link: https://doi.org/10.1016/..
 
?
12

88P Adverse events (AEs) as potential predictive factors of..:

Persano, M. ; Rimini, M. ; Tada, T....
Immuno-Oncology and Technology.  20 (2023)  - p. 100560 , 2023
Link: https://doi.org/10.1016/..
 
?
13

78P Clinical outcomes with atezolizumab plus bevacizumab (A..:

Persano, M. ; Rimini, M. ; Cascinu, S...
Immuno-Oncology and Technology.  16 (2022)  - p. 100182 , 2022
Link: https://doi.org/10.1016/..
 
?
14

111P Identification of atezolizumab plus bevacizumab progno..:

Persano, M. ; Rimini, M. ; Cascinu, S...
Immuno-Oncology and Technology.  16 (2022)  - p. 100215 , 2022
Link: https://doi.org/10.1016/..
 
?
15

108P Role of the prognostic nutritional index in predicting..:

Persano, M. ; Rimini, M. ; Cascinu, S...
Immuno-Oncology and Technology.  16 (2022)  - p. 100212 , 2022
Link: https://doi.org/10.1016/..
 
1-15